2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 299

Minimally Important Differences for Four Patient-Reported Outcomes Measurement Information System (PROMIS) Short Forms: Physical Function, Pain Interference, Depression, and Anxiety Among Adults with Knee Osteoarthritis
Abstract Number: 3253

Minimum Physical Function Needed to Walk 6000 Steps/Day in People with Knee Osteoarthritis
Abstract Number: 249

MiR-204-3p Associates with an Increased Level of IL-6 in Familial Mediterranean Fever By Targeting the PIK3 Signaling Pathway
Abstract Number: 3231

miR200b-5p Expression in Minor Salivary Glands (MSG): A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?
Abstract Number: 3075

Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population
Abstract Number: 2492

Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Abstract Number: 1862

Modelling Healthy and Scleroderma Fibrotic Skin in Vitro: Mechanical Stress Alters Macrophage Cytokine Expression and Triggers Signalling Via the Mechano-Sensing Transcription Factor Myocardin-Related Transcription Factor-a
Abstract Number: 3227

Modelling Primary Sjögren’s Syndrome Using Salivary Gland Stem Cells
Abstract Number: 1861

Modelling the Interaction Between Disease Microenvironment and Mesenchymal Cells in Systemic Sclerosis
Abstract Number: 2230

Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Abstract Number: 1470

Moderate to Severe Disease Activity in Rheumatoid Arthritis Is Associated with Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake
Abstract Number: 24

Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Abstract Number: 1461

Modification of Proteins with Malondialdehyde-Acetaldehyde and Citrulline Elicit Antibody Responses in DBA/1J Mice
Abstract Number: 2697

Modulator Role of Inducible Costimulator (ICOS) in Spondyloarthritis Animal Model
Abstract Number: 432

Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].